期刊文献+

超声联合血清糖类抗原125、糖类抗原19-9诊断卵巢癌的临床价值 被引量:6

Clinical value of ultrasound combined with serum carbohydrate antigen 125 and carbohydrate antigen 19-9 in the diagnosis of ovarian cancer
下载PDF
导出
摘要 目的探究超声联合血清糖类抗原125(CA125)、糖类抗原19-9(CA19-9)对卵巢癌的临床诊断价值。方法选取卵巢癌患者47例作为观察组,同期卵巢良性疾病患者60例作为对照组。两组患者术前均实施超声检查和血清CA125、CA19-9检测。统计两组患者超声评分、血流阻力指数(RI)、血清CA125和CA19-9水平,对比不同分期观察组患者超声评分、RI、血清CA125和CA19-9水平,并对超声、血清CA125、血清CA19-9单独及联合检测对卵巢癌的诊断价值进行分析。结果观察组患者超声评分、血清CA125和CA19-9水平均明显高于对照组,RI明显低于对照组,差异均有统计学意义(P﹤0.01)。Ⅰ、Ⅱ期卵巢癌患者超声评分、血清CA125和CA19-9水平均明显低于Ⅲ、Ⅳ期患者,RI明显高于Ⅲ、Ⅳ期患者,差异均有统计学意义(P﹤0.01)。受试者工作特征(ROC)曲线分析结果显示,超声检查、血清CA125、血清CA19-9联合检测对卵巢癌的曲线下面积高于各项指标单一检测(P﹤0.01)。结论超声、血清CA125、CA19-9三者联合能将各自优势相互结合,有效提高卵巢癌的诊断价值。 Objective To study the value of serum carbohydrate antigen 125(CA125) and carbohydrate antigen 19-9(CA19-9) in the diagnosis of ovarian cancer.Method A total of 47 patients with ovarian cancer were selected as the observation group,and 60 patients with benign ovarian diseases were selected as the control group.Ultrasound examination and the detection of serum CA125 and CA19-9 were performed in both groups before operation. The ultrasonic score,blood flow resistance index(RI),serum CA125 and CA19-9 levels of the two groups were counted.The ultrasonic score,RI,serum CA125 and CA19-9 levels of patients in different pathological stages of the observation group were compared.The diagnostic value of ultrasound,serum CA125 and serum CA19-9 in ovarian cancer were analyzed.Result The ultrasound score,serum CA125 and CA19-9 levels in the observation group were significantly higher than those in the control group,and RI was significantly lower than that in the control group,and the differences were statistically significant(P<0.01).The ultrasound score,serum CA125 and CA19-9 levels of patients with stage Ⅰ and Ⅱ ovarian cancer were significantly lower than those of patients with stage Ⅲ and Ⅳ,and RI was significantly higher than that of patients with stageⅢ and Ⅳ,and the differences were statistically significant(P<0.01).Receiver operating characteristic(ROC) curve analysis showed that the area under the curve of the combined detection of ultrasound,serum CA125 and serum CA19-9 for ovarian cancer was higher than that of single detection of each index(P<0.01).Conclusion The combination of ultrasound,serum CA125 and CA19-9 can combine the respective advantages with each other,and can effectively improve the diagnostic accuracy of the ovarian cancer.
作者 郝淑琴 郝学民 王慧梅 刘金阁 HAO Shuqin;HAO Xuemin;WANG Huimei;LIU Jin’ge(Department of Ultrasound,Xinxiang First People’s Hospital,Xinxiang 453000,He’nan,China;Department of Neurology,He’nan Xinhe Hospital,Xinyang 464000,He’nan,China;Department of Anesthesiology,Luoyang Union Hospital,Luoyang 471000,He’nan,China)
出处 《癌症进展》 2021年第6期581-584,共4页 Oncology Progress
关键词 卵巢癌 彩色多普勒超声 糖类抗原125 糖类抗原19-9 诊断 ovarian cancer color doppler ultrasound carbohydrate antigen 125 carbonhydrate antigen 19-9 diagnosis
  • 相关文献

参考文献17

二级参考文献148

  • 1班慧敏.血清CA125、CA199、和CA724联合检测对卵巢癌的诊断价值[J].中国当代医师,2011,18(17):38.
  • 2Kadija Sasa, Stefanovic Aleksandar,Jerem ic Katarina, etal. The Utility of Human Epididymal Protein 4,Cancer Antigen 125, and Risk for Malignancy Algorithm in Ovarian Cancer and Endom etriosis[J]. International Journal of Gynecological Cancer, 2012, 22(2) :238.
  • 3Fioretti P Gaddueei A, Ferdeghini M et al. The concomitant de termination of dierent serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow up of patients [J]. Gynecol Onco1,1992,44:155.
  • 4Liu JF, Kindelberger D, Doyle C, et al. Predictive value of circulating tumor cells (CTCs) in newly- diagnosed and recurrent ovarian cancer patients[J]. Gynecol Oncol, 2013,131(2) :352 -356.
  • 5Obermayr E, Castillo - Tong DC, Pils D, et al. Molecular characteriza- tion of circulating tumor cells in patients with ovarian cancer improves their prognostic significance - a study of the OVCAD consortium [ J ]. Gynecol Oncol, 2013,128 ( 1 ) : 15 - 21.
  • 6Kaijser J, Bourne T, Valentin L, et al. Improving strategies for diagno- sing ovarian cancer: a summary of the International Ovarian Tumor Anal- ysis (IOTA) studies[J]. Ultrasound Obstet Gynecol, 2013,41 (1):9 - 20.
  • 7Lawicki S, Gacuta - Szumarska E, Bedkowska GE, et al. Hematopoiet- ic cytokines as tumor mm'kers in gynecological malignancies. A multiva- riate analysis in epithelial ovarian cancer patients [ J ]. Growth Factors, 2012,30(6) :357 -366.
  • 8Sang M, Wu X, Fan X, et al. Multiple MAGE - A genes as surveil- lance marker for the detection of circulating tumor cells in patients with ovarian cancer[ J]. Biomarkers, 2014,19( 1 ) :34 -42.
  • 9Alanbay I, Akturk E, Coksuer H, et al. Comparison of risk of malig- nancy index (RMI), CA125, CA 19-9, ultrasound score, and meno- pausal status in borderline ovarian tumor [ J ]. Gynecol Endocrinol, 2012,28(6) :478 -482.
  • 10Illueca C, Machado I, Gareia A, et al. Uncommon vascular tumor of the ovary. Primary ovarian epithelioid hemangioendothelioma or vascular sarcomatous transformation in ovarian germ cell tumor[ J] ? Arch Gyne- col Obstet, 2011,284(6) :1589 - 1591.

共引文献328

同被引文献90

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部